Wall Street brokerages predict that Insys Therapeutics Inc (NASDAQ:INSY) will post $22.61 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Insys Therapeutics’ earnings, with estimates ranging from $20.93 million to $23.60 million. Insys Therapeutics reported sales of $30.67 million in the same quarter last year, which indicates a negative year over year growth rate of 26.3%. The firm is scheduled to announce its next quarterly earnings results after the market closes on Monday, November 5th.
On average, analysts expect that Insys Therapeutics will report full-year sales of $93.39 million for the current year, with estimates ranging from $89.69 million to $95.60 million. For the next year, analysts anticipate that the firm will report sales of $99.22 million, with estimates ranging from $90.78 million to $107.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Insys Therapeutics.
Insys Therapeutics (NASDAQ:INSY) last announced its quarterly earnings results on Wednesday, August 8th. The specialty pharmaceutical company reported ($0.33) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.17). Insys Therapeutics had a negative net margin of 238.31% and a negative return on equity of 130.43%. The business had revenue of $23.47 million during the quarter, compared to the consensus estimate of $25.91 million. During the same period in the previous year, the business posted $0.03 EPS. Insys Therapeutics’s revenue was down 44.9% compared to the same quarter last year.
Institutional investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC bought a new position in shares of Insys Therapeutics during the 2nd quarter worth approximately $131,000. Creative Planning bought a new position in shares of Insys Therapeutics during the 3rd quarter worth approximately $153,000. JPMorgan Chase & Co. lifted its position in shares of Insys Therapeutics by 303.5% during the 1st quarter. JPMorgan Chase & Co. now owns 25,624 shares of the specialty pharmaceutical company’s stock worth $155,000 after buying an additional 19,273 shares in the last quarter. BNP Paribas Arbitrage SA lifted its position in shares of Insys Therapeutics by 47.4% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 31,105 shares of the specialty pharmaceutical company’s stock worth $225,000 after buying an additional 10,001 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. lifted its position in shares of Insys Therapeutics by 33.7% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 126,335 shares of the specialty pharmaceutical company’s stock worth $915,000 after buying an additional 31,840 shares in the last quarter. 18.02% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ INSY traded down $0.04 during trading hours on Monday, hitting $7.59. The company’s stock had a trading volume of 310,900 shares, compared to its average volume of 912,750. Insys Therapeutics has a 52 week low of $4.10 and a 52 week high of $14.00. The stock has a market cap of $566.49 million, a price-to-earnings ratio of -15.49 and a beta of 1.65.
About Insys Therapeutics
Insys Therapeutics, Inc, a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS.
Featured Article: Hedge Funds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.